AURA
Aura Biosciences, Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
7.80
▲ 0.03 (0.39%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
7.55
Prev close
7.77
Day high
8.09
Day low
7.65
Volume
490.74K
Market cap
—
P/E (TTM)
—
52W range
4.73 – 9.54
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+1.43%
+2.8%
1M
+8.33%
+4.6%
3M
+1.96%
-1.1%
6M
+44.18%
+33.1%
YTD
+43.12%
+30.8%
1Y
+22.45%
+2.5%
3Y
-21.92%
-96.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $90.30M | $73.30M | $65.23M | $42.24M | +23.2% |
| Selling, general & admin | $22.49M | $22.81M | $19.76M | $18.06M | -1.4% |
| Total operating expense | $112.79M | $96.12M | $84.99M | $60.30M | +17.3% |
| Operating income | -$112.79M | -$96.12M | -$84.99M | -$60.30M | -17.3% |
| Net interest income | $6.63M | $9.43M | $8.59M | $1.86M | -29.7% |
| Pre-tax income | -$106.08M | -$86.81M | -$76.27M | -$58.76M | -22.2% |
| Tax provision | $108.00K | $112.00K | $137.00K | $0 | -3.6% |
| Net income | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -22.2% |
| Net income to common | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -22.2% |
| Basic EPS | -1.76 | -1.75 | -1.93 | -1.96 | -0.6% |
| Diluted EPS | -1.76 | -1.75 | -1.93 | -1.96 | -0.6% |
| EBIT | -$112.79M | -$96.12M | -$84.99M | -$60.30M | -17.3% |
| EBITDA | -$111.66M | -$94.89M | -$83.70M | -$59.12M | -17.7% |
| Basic shares | 60.34M | 49.65M | 39.62M | 29.94M | +21.5% |
| Diluted shares | 60.34M | 49.65M | 39.62M | 29.94M | +21.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $59.52M | $31.69M | $41.06M | $121.58M | +87.8% |
| Cash & short-term investments | $144.24M | $151.09M | $226.15M | $188.81M | -4.5% |
| Total current assets | $149.74M | $160.62M | $231.79M | $196.70M | -6.8% |
| Property, plant & equipment | $18.45M | $20.59M | $22.00M | $26.04M | -10.4% |
| Total assets | $169.43M | $182.50M | $255.07M | $223.94M | -7.2% |
| Total current liabilities | $18.38M | $14.91M | $12.36M | $10.46M | +23.3% |
| Total debt | $17.38M | $18.77M | $19.56M | $20.86M | -7.4% |
| Total liabilities | $32.52M | $30.53M | $29.23M | $28.35M | +6.5% |
| Retained earnings | -$480.42M | -$374.23M | -$287.31M | -$210.90M | -28.4% |
| Shareholder equity | $136.91M | $151.97M | $225.85M | $195.58M | -9.9% |
| Working capital | $131.36M | $145.71M | $219.44M | $186.25M | -9.9% |
| Net tangible assets | $136.91M | $151.97M | $225.85M | $195.58M | -9.9% |
| Shares issued | 63.59M | 50.00M | 49.35M | 37.77M | +27.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -22.2% |
| Depreciation & amortisation | $1.13M | $1.22M | $1.29M | $1.18M | -7.7% |
| Stock-based compensation | $14.32M | $11.72M | $8.77M | $6.41M | +22.1% |
| Change in working capital | $5.97M | -$2.64M | $4.44M | -$3.85M | +326.0% |
| Operating cash flow | -$84.74M | -$79.81M | -$63.85M | -$54.60M | -6.2% |
| Capital expenditure | -$447.00K | -$1.25M | -$709.00K | -$1.09M | +64.3% |
| Investing cash flow | $35.59M | $68.82M | -$113.96M | -$67.87M | -48.3% |
| Financing cash flow | $77.16M | $1.59M | $97.29M | $95.63M | +4,737.3% |
| Free cash flow | -$85.19M | -$81.06M | -$64.56M | -$55.70M | -5.1% |
| End cash position | $60.28M | $32.46M | $41.85M | $122.37M | +85.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $27.96M | $21.90M | $22.18M | $22.88M | $23.34M | +27.7% |
| Selling, general & admin | $6.91M | $5.34M | $5.73M | $5.73M | $5.69M | +29.3% |
| Total operating expense | $34.87M | $27.24M | $27.91M | $28.61M | $29.04M | +28.0% |
| Operating income | -$34.87M | -$27.24M | -$27.91M | -$28.61M | -$29.04M | -28.0% |
| Net interest income | $1.19M | $1.54M | $1.81M | $1.68M | $1.59M | -22.9% |
| Pre-tax income | -$33.67M | -$25.54M | -$26.10M | -$26.97M | -$27.46M | -31.8% |
| Tax provision | $11.00K | $15.00K | $26.00K | $48.00K | $18.00K | -26.7% |
| Net income | -$33.69M | -$25.56M | -$26.13M | -$27.02M | -$27.48M | -31.8% |
| Net income to common | -$33.69M | -$25.56M | -$26.13M | -$27.02M | -$27.48M | -31.8% |
| Basic EPS | -0.50 | — | -0.40 | -0.47 | -0.55 | — |
| Diluted EPS | -0.50 | — | -0.40 | -0.47 | -0.55 | — |
| EBIT | -$34.87M | -$27.24M | -$27.91M | -$28.61M | -$29.04M | -28.0% |
| EBITDA | -$34.59M | -$26.96M | -$27.63M | -$28.33M | -$28.74M | -28.3% |
| Basic shares | 67.45M | — | 65.94M | 58.02M | 50.13M | — |
| Diluted shares | 67.45M | — | 65.94M | 58.02M | 50.13M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.79M | $59.52M | $47.55M | $107.37M | $38.23M | +42.5% |
| Cash & short-term investments | $114.73M | $144.24M | $161.87M | $177.31M | $127.99M | -20.5% |
| Total current assets | $118.50M | $149.74M | $170.12M | $183.96M | $134.52M | -20.9% |
| Property, plant & equipment | $17.89M | $18.45M | $18.86M | $19.49M | $20.12M | -3.1% |
| Total assets | $137.68M | $169.43M | $190.02M | $204.40M | $155.40M | -18.7% |
| Total current liabilities | $16.71M | $18.38M | $18.82M | $14.85M | $12.16M | -9.1% |
| Total debt | $16.99M | $17.38M | $17.75M | $18.11M | $18.44M | -2.2% |
| Total liabilities | $30.43M | $32.52M | $33.36M | $29.77M | $27.43M | -6.4% |
| Retained earnings | -$514.10M | -$480.42M | -$454.86M | -$428.73M | -$401.71M | -7.0% |
| Shareholder equity | $107.25M | $136.91M | $156.67M | $174.63M | $127.97M | -21.7% |
| Working capital | $101.80M | $131.36M | $151.30M | $169.11M | $122.35M | -22.5% |
| Net tangible assets | $107.25M | $136.91M | $156.67M | $174.63M | $127.97M | -21.7% |
| Shares issued | 64.15M | 63.59M | 62.99M | 62.07M | 50.23M | +0.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$33.69M | -$25.56M | -$26.13M | -$27.02M | -$27.48M | -31.8% |
| Depreciation & amortisation | $274.00K | $272.00K | $280.00K | $286.00K | $291.00K | +0.7% |
| Stock-based compensation | $3.82M | $3.28M | $3.69M | $3.83M | $3.51M | +16.5% |
| Change in working capital | -$426.00K | $1.56M | $1.96M | $2.03M | $423.00K | -127.3% |
| Operating cash flow | -$29.89M | -$20.47M | -$20.14M | -$20.77M | -$23.36M | -46.0% |
| Capital expenditure | -$102.00K | -$176.00K | -$45.00K | -$39.00K | -$187.00K | +42.0% |
| Investing cash flow | $54.90M | $29.82M | -$44.02M | $19.98M | $29.81M | +84.1% |
| Financing cash flow | $300.00K | $2.77M | $4.36M | $69.93M | $96.00K | -89.2% |
| Free cash flow | -$30.00M | -$20.64M | -$20.19M | -$20.81M | -$23.54M | -45.3% |
| End cash position | $85.56M | $60.28M | $48.32M | $108.14M | $38.99M | +41.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.80
-0.04% from price
SMA 20
7.52
+3.69% from price
SMA 50
7.14
+9.25% from price
SMA 100
7.20
+8.27% from price
SMA 200
6.50
+20.09% from price
EMA 12
7.71
+1.12% from price
EMA 26
7.50
+3.94% from price
EMA 50
7.32
+6.60% from price
RSI (14)
56.6
Neutral
MACD (12,26,9)
0.21
Hist 0.01
ATR (14)
0.50
6.37% of price
Realised vol 30D
42.4%
Annualised
Bollinger upper
8.28
20, 2σ
Bollinger lower
6.77
20, 2σ
50 / 200 cross
Golden
7.14 vs 6.50
Trend bias
Above 200
+20.09%
Risk profile
Beta vs SPY
1.10
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
42.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-31.2%
Peak to trough
Max drawdown 5Y
-80.3%
Peak to trough
ATR 14
0.50
6.37% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Aura Biosciences Q2 Loss Widens
MT Newswires · 11d ago
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 12d ago
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
GlobeNewswire · 46d ago
Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma
MT Newswires · 82d ago
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
GlobeNewswire · 82d ago
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
MarketBeat · 87d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.